McKesson, CD&R Near $5B+ Deal for Option Care Health

McKesson Corporation, a global leader in healthcare supply chain management, and private equity firm Clayton, Dubilier & Rice (CD&R) are nearing a definitive agreement to acquire Option Care Health, a prominent provider of home infusion services. The transaction is valued at more than $5 billion, according to sources familiar with the matter. This potential acquisition represents a significant move within the healthcare services sector, signaling a trend of larger companies and investment firms targeting undervalued assets in the industry. Option Care Health specializes in delivering complex therapies and clinical support to patients in their homes, offering an alternative to traditional hospital settings. The company's services include infusion therapy, specialty pharmacy, and home healthcare, catering to patients with chronic and acute conditions.

CD&R has a history of investing in healthcare companies, aiming to drive operational improvements and long-term growth. Their involvement suggests a strategic approach to enhancing Option Care Health's capabilities and market position. McKesson, on the other hand, is a Fortune 500 company that distributes pharmaceuticals and medical supplies, and also provides technology solutions and services to healthcare providers. Integrating Option Care Health's home infusion services could complement McKesson's existing portfolio, potentially creating synergies in patient care delivery and supply chain efficiency. The deal, if finalized, would be one of the largest buyouts in the healthcare services space in recent times, reflecting the sector's attractiveness to investors seeking stable, recurring revenue streams and opportunities for consolidation.

The healthcare services landscape has seen increased activity, with private equity firms actively pursuing acquisitions of companies that offer specialized care and demonstrate strong patient outcomes. Option Care Health's focus on home-based care aligns with a broader shift towards decentralized healthcare models, which can offer cost savings and improved patient convenience. The company operates a network of pharmacies and infusion centers across the United States, serving a diverse patient population. Its acquisition by McKesson and CD&R could lead to expanded service offerings and geographic reach.

While the terms of the deal are not yet public, the reported valuation of over $5 billion underscores the perceived value and growth potential of Option Care Health. The transaction is expected to be funded through a combination of debt and equity. Regulatory reviews and customary closing conditions will need to be met before the acquisition can be completed. The finalization of this deal would mark a significant development for McKesson and CD&R, further solidifying their presence in the healthcare industry and potentially reshaping the competitive dynamics within the home infusion services market.